• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.

作者信息

D'Silva Kristin M, Serling-Boyd Naomi, Hsu Tiffany Y-T, Sparks Jeffrey A, Wallace Zachary S

机构信息

Rheumatology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.

DOI:10.1136/annrheumdis-2020-219808
PMID:33436385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8482283/
Abstract
摘要

相似文献

1
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.风湿性疾病患者感染新冠病毒后对严重急性呼吸综合征冠状病毒2的抗体反应。
Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.
2
Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'.关于“风湿性疾病患者感染 COVID-19 后对 SARS-CoV-2 的抗体反应”的通信
Ann Rheum Dis. 2023 Jun;82(6):e130. doi: 10.1136/annrheumdis-2021-220148. Epub 2021 Mar 10.
3
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的高抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
4
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.接种疫苗的系统性自身免疫性风湿病患者中新冠病毒突破性感染的临床特征与结局
Ann Rheum Dis. 2022 Feb;81(2):289-291. doi: 10.1136/annrheumdis-2021-221326. Epub 2021 Sep 6.
5
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
6
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
7
Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.影响炎症性风湿性疾病中COVID-19病程的因素。
Clin Exp Rheumatol. 2023 Mar;41(3):758-759. doi: 10.55563/clinexprheumatol/3pcfrz. Epub 2022 Oct 13.
8
Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.慢性传统改善病情抗风湿药物掩盖了一名老年风湿性疾病患者的严重新型冠状病毒肺炎表现。
J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.043. Epub 2020 May 29.
9
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
10
SARS-CoV-2 seroprevalence in patients with autoimmune rheumatic diseases versus family controls: a multi-city cross-sectional survey.SARS-CoV-2 血清阳性率在自身免疫性风湿病患者与家族对照者中的比较：一项多城市横断面研究。
Rheumatol Int. 2024 Jan;44(1):81-87. doi: 10.1007/s00296-023-05489-x. Epub 2023 Oct 31.

引用本文的文献

1
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.改善病情抗风湿药与系统性自身免疫性风湿病患者新冠病毒病急性后遗症的关联：一项前瞻性研究
Rheumatology (Oxford). 2024 Oct 1;63(10):2828-2837. doi: 10.1093/rheumatology/kead662.
2
Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.体液免疫针对地方性冠状病毒与风湿性疾病患者 COVID-19 的急性后期后遗症有关。
Sci Transl Med. 2023 Sep 6;15(712):eadf6598. doi: 10.1126/scitranslmed.adf6598.
3
Considerations for Pharmacologic Management of Rheumatoid Arthritis in the COVID-19 Era: a Narrative Review.2019冠状病毒病（COVID-19）大流行期间类风湿关节炎的药物治疗考量：一篇叙述性综述
Curr Rheumatol Rep. 2023 Nov;25(11):236-245. doi: 10.1007/s11926-023-01111-y. Epub 2023 Aug 19.
4
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.COVID-19 时期血管炎患者的免疫抑制管理。
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
5
Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19.交叉冠状病毒免疫在新冠后遗症中的影响。
medRxiv. 2022 Sep 26:2022.09.25.22280335. doi: 10.1101/2022.09.25.22280335.
6
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study.免疫介导性炎症疾病患者中SARS-CoV-2疫苗接种反应的强度和持久性：一项前瞻性队列研究。
Lancet Rheumatol. 2022 Sep;4(9):e614-e625. doi: 10.1016/S2665-9913(22)00191-6. Epub 2022 Aug 9.
7
Humoral and cellular response in convalescent COVID-19 lupus patients.恢复期 COVID-19 狼疮患者的体液和细胞反应。
Sci Rep. 2022 Aug 12;12(1):13787. doi: 10.1038/s41598-022-17334-5.
8
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.COVID-19 患者中系统性自身免疫性风湿病的时间趋势：从第一波到最初的奥密克戎波。
Ann Rheum Dis. 2022 Dec;81(12):1742-1749. doi: 10.1136/ard-2022-222954. Epub 2022 Aug 9.
9
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.葡萄牙炎症性风湿病患者感染的危险因素、重症疾病预测因素及对 COVID-19 的抗体反应——一项多中心全国性研究
Front Med (Lausanne). 2022 Jun 13;9:901817. doi: 10.3389/fmed.2022.901817. eCollection 2022.
10
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.系统性自身免疫性风湿病患者中 COVID-19 结局的时间趋势：从第一波疫情到奥密克戎毒株时期
medRxiv. 2022 Jun 20:2022.06.19.22276599. doi: 10.1101/2022.06.19.22276599.

本文引用的文献

1
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.医护人员中抗SARS-CoV-2抗体状态及感染发生率
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.大流行 6 个月后患风湿性疾病患者的 2019 年冠状病毒病结局。
Ann Rheum Dis. 2021 May;80(5):660-666. doi: 10.1136/annrheumdis-2020-219279. Epub 2020 Nov 30.
4
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
5
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.新冠病毒（COVID-19）中 Bcl-6 表达的滤泡辅助性 T 细胞和生发中心的缺失。
Cell. 2020 Oct 1;183(1):143-157.e13. doi: 10.1016/j.cell.2020.08.025. Epub 2020 Aug 19.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.